Kornimate/medical-research-clean huggingface dataset:
left ventricular physiological effects of veno-arterial extracorporeal membrane oxygenation support during cardiogenic shock

Conditions: Acute Coronary Syndrome; Cardiogenic Shock

Summary: a clinical events committee (cec) will include cardiac surgery professor and chief of cardiac surgery rose kelly md, professor of medicine ganesh raveendran md at the university of minnesota who is the direction of interventional cardiology and professor of medicine at the university of minnesota david benditt. they will review and adjudicate serious and unexpected adverse events independently from the pi and co investigators.


Eligibility criteria:
inclusion criteria: * age 18-75 years * scai d/e cs requiring va-ecmo support based on treating team's judgement. * map \>65 mmhg on \<3 vasopressors/inotropes at the time of consent * cardiogenic shock due to acute coronary syndrome identified by coronary angiography at the index hospitalization per standard cardiology practice exclusion criteria: * va-ecmo for sepsis, pulmonary embolism, covid-19 related cardiorespiratory failure, severe rv failure due to severe idiopathic pulmonary hypertension * cs due to other (non-acs) etiologies * known patient with severe left ventricular dysfunction and stage iv nyha heart failure being evaluated for or with a history of lvad and transplantation prior to commencement of va-ecmo * profound vasoplegia with map \<65 mmhg on 3 vasopressors/inotropes * moderate to severe aortic regurgitation (contraindication to va-ecmo) * moderate to severe aortic stenosis (contraindication to lv instrumentation with pv loop catheter) * bleeding complications requiring ongoing transfusions of blood products * ischemic lower extremities * evidence of circuit thrombosis or fibrin accumulation (turndown increases risk for stroke and clot formation) * evidence of sepsis or septic shock * evidence of lv thrombus on echocardiography (contraindication for accessing lv cavity with catheters)

Keywords: acute coronary syndrome cardiogenic shock left ventricle va-ecmo
alzheimer prevention trials (apt) webstudy

Conditions: Alzheimer Disease; Dementia

Summary: the goal of the alzheimer prevention trials (apt) webstudy is to accelerate enrollment for alzheimer's disease (ad) clinical trials by identifying and tracking individuals who may be at higher risk for developing ad dementia.

the apt webstudy will use web-based cognitive testing and questionnaires to generate a risk score which will be used to identify individuals who may be at an increased risk for developing ad dementia. individuals who join the apt webstudy will register at https://www.aptwebstudy.org/, sign an electronic informed consent form (icf), provide basic demographic information and participate in web-based cognitive testing. participants will return the apt webstudy quarterly (every 3 months) to complete the cognitive testing again. based on the risk score and changes identified in the cognitive testing results, participants will be invited to visit a partnering clinical trial site for an in-person visit with biomarker testing and clinical assessment. the combined results of the web-based assessments, with the biomarker and clinical assessments, will allow an adaptive statistical algorithm to improve the selection of those at highest risk for developing ad. to join the apt webstudy, please visit https://www.aptwebstudy.org/.

Eligibility criteria:
inclusion criteria: * male or female at least 50 years of age * no evidence of dementia * willing to participate in remote longitudinal cognitive testing and possible referral for biomarker assessment based on risk exclusion criteria: * n/a. anyone can register for the apt webstudy, however, only individuals identified using the risk algorithm will be referred for in-person biomarker assessments.

Keywords: alzheimer's prevention web-based
conduction system stimulation to avoid left ventricle dysfunction

Conditions: Atrioventricular Block, Second and Third Degree; Pacemaker-Induced Cardiomyopathy; Heart Failure

Summary: the aim of the study is to demonstrate that conduction system pacing (csp) can preserve a normal ventricular function compared to right ventricular apical pacing (rvap) in patients with pre-implant preserved left ventricular ejection fraction (lvef) and a high burden of expected ventricular pacing due to atrioventricular conduction block (av block). after informed consent signature, patients with high degree av block and normal lvef will be randomized to permanent pacemaker stimulation with csp vs rvap. all the patients have a complete evaluation before the procedure and at 3 and 6 months follow-up.

the stay trial (conduction system stimulation to avoid left ventricle dysfunction) is a single-center, prospective, randomized, parallel, controlled study, comparing mid-term outcomes in a population undergoing pacemaker implantation due to a high degree atrio-ventricular block (avb). the study was approved by the hospital ethics committee, in accordance with the declaration of helsinki. all patients signed informed consent and were implanted between september 2019 until december 2022 in a 1:1 randomized fashion to conventional rvap vs csp (hbs or lbbs). randomization was performed during the pre-procedural antibiotic infusion. all the patients have a complete evaluation before the procedure and at 3 and 6 months follow-up, including demographic and clinical characteristics, physical examination, twelve-lead ecg, minnesota score (mlwhfq), and blood test with nt-probnp determination. patients also have a transthoracic echography before the procedure and at 6 months follow-up. at 6 months echocardiographic and clinical data will be compared.

Eligibility criteria:
inclusion criteria: 1. age of 18 years or more 2. preserved or mild deteriorated lvef (simpson \>40%) assessed by a recent (\<1 month before implantation) transthoracic echocardiography. 3. indication for pacing based on the presence of a high degree avb, and consequently with an anticipated high burden of ventricular pacing (\>50%). 4. live expectancy of more than 6 months and capability to understand the protocol, signing the informed consent form and accomplish the follow-up. exclusion criteria: 1. indication for implantable cardioverter defibrillator device. 2. patients with previous lvd and a recovered lvef 3. history of myocardial infarction/revascularization or cardiac surgery within 6 months before randomization 4. pregnancy, active cancer treatment, or participation in another clinical trial with active treatment.
osi-774 (tarceva) plus gemcitabine in patients with locally advanced, unresectable or metastatic pancreatic cancer.

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to determine if osi-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.


Eligibility criteria:
inclusion criteria: histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas;cancer which is unresectable, locally advanced or metastatic. must have evidence of disease (clinical or radiological). male or female, 18 years or older. patients may have received prior radiation treatment for management of local disease providing that disease progression has been documented. all toxicities have resolved, and the last fraction of radiation treatment was completed at least 4 weeks prior to randomization. patients may not have received prior chemotherapy, other then 5fu (+/- folic acid) or gemcitabine given concurrently with radiation treatment as a 'radiosensitiser.'

Keywords: tarceva, egfr, erlotinib, osi-774
results of gamma nail in trochentric fractures of the adults

Conditions: Trochanteric Fractures

Summary: we prospectively reviewed the results of 30 patients who had undergone intramedullary fixation with a gamma nail for femur trochentric fractures in auh. within 1 year

hip fractures are considered one of the major health problems in aging societies . these fractures are correlated with increased disability and mortality and a decreased quality of life . early mobilization of patients with these fractures is essential to improve fracture healing, minimize immediate postsurgical morbidity, and reduce care costs. one essential prerequisite for early mobilization is mechanically stable fracture fixation . nowadays, most hip fractures are treated by extramedullary or intramedullary implants, which allow a stable fixation in the majority of cases a dynamic hip screw (dhs) is the most commonly used implant for intertrochanteric fractures . load bearing in the proximal femur is predominantly through the intact calcar femoral; the lever arm of the laterally placed plate is increased, thus, there is a risk of implant cutout if the calcar is not intact . biomechanically, compared with a laterally fixed side plate, an intramedullary device decreases the bending force of the hip joint on the implant by 25-30%. this has advantages especially in elderly patients, in whom the primary treatment goal is immediate full weight-bearing mobilization. it has been postulated that cephalomedullary nails have an advantage over dhs fixation because of the load-bearing axis being closer to the hip joint fulcrum, and also less blood loss, minimal tissue dissection, shorter operation time, and faster ambulation after surgery . however, other studies have reported that fixation with dhs is better . one of the major drawbacks discovered with the use of the gamma nail is a higher reoperation rate as a result of new fracture around the implant . in this study, we present our results for the treatment of trochentric fractures using a gamma nail in terms of the outcome, drawbacks, and possible complications.

Eligibility criteria:
inclusion criteria: * age (20-70) * unstable trochentric fractures exclusion criteria: * pathological fractures due to neoplasia

Keywords: gamma nail
local open-label access study for patients who completed a1481244 study in brazil

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study is to provide sildenafil therapy to patients who completed the a1481244 study for the treatment of pah, and reside in brazilian states where revatio™ is not supplied by health secretary, and are judged by the investigator to derive clinical benefit from continued treatment with sildenafil. it will be supplied until patient gets access to sildenafil through brazilian state health secretary from where patient resides.


Eligibility criteria:
inclusion criteria: * subject who completed the a1481244 study and are judged by the investigator to derive clinical benefit from continuous treatment with sildenafil 20 mg therapy. * subject who resides in a brazilian state where sildenafil is not supplied by state health secretary. exclusion criteria: * pregnant or lactating women. * current participation in other studies and during study participation.

Keywords: open label sildenafil pah brazil
study to assess the efficacy and safety of ublituximab + umbralisib with or without bendamustine and umbralisib alone in patients with previously treated non-hodgkins lymphoma

Conditions: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Small Lymphocytic Lymphoma

Summary: unity nhl - a phase 2b randomized study to assess the efficacy and safety of the combination of ublituximab + umbralisib with or without bendamustine and umbralisib alone in patients with previously treated non-hodgkin's lymphoma

the purpose of this study is to evaluate the efficacy and safety of umbralisib monotherapy and the umbralisib + ublituximab (u2) combination in aggressive and indolent lymphomas and to also explore the u2 regimen in combination with bendamustine in the treatment of nhl (fl, sll, mzl, dlbcl and mcl).

Eligibility criteria:
inclusion criteria: * diagnosis of non-hodgkin's lymphoma including follicular, mantle cell lymphoma and marginal zone lymphoma * relapsed or refractory to prior standard therapy and subjects who are not candidates for high-dose therapy or autologous stem cell transplant * mcl subjects with one or more lines of therapy including at least one btk inhibitor (ibrutinib, acalabrutinib or zanibrutinib only) exclusion criteria: * any major surgery, chemotherapy or immunotherapy within the last 21 days * evidence of hepatitis b virus, hepatitis c virus or known hiv infection * autologous hematologic stem cell transplant within 6 months of study entry. prior allogeneic hematologic stem cell transplant is excluded * prior therapy with a pi3k delta inhibitor

Keywords: dlbcl fl mzl mcl sll non-hodgkin's lymphoma
laminaria compared to dilapan-s for cervical preparation before dilation and evacuation at 18-24 weeks of gestation

Conditions: Second Trimester Abortion

Summary: primary objective: to study the difference in dilation and evacuation (d\&e) procedure time following overnight cervical preparation with laminaria or dilapan-s™. the investigators hypothesize procedure time will be less with dilapan-s™. secondary objectives: to compare the use of laminaria and dilapan-s™ for differences in: (1) initial cervical dilation before d\&e; (2) need for mechanical dilation to accomplish d\&e and ease of dilation if required; (3) number of osmotic dilators placed; (4) ability to complete the d\&e procedure without further cervical preparation; (5) complications; (6) pain and other side effects; (7) patient acceptability; and (8) provider acceptability.

one hundred eighty women were randomized evenly across treatment arms, stratified by gestational age groups of 18 0/7-20 6/7 (n= 91) and 21 0/7-24 0/7 (n=87). the analytic sample n=173 (laminaria=86, dilapan=87); 2 cases were removed for post-randomization exclusion and 5 for missing data on one or more outcome variables. demographic information and results for the primary outcome of procedure time are reported below in tabular form in the results section.

Eligibility criteria:
inclusion criteria: * 18 years of age and older * seeking pregnancy termination from 18 0/7 to 24 0/7 weeks of gestation * eligible for pregnancy termination at planned parenthood of new york city * able to give informed consent * english speaking exclusion criteria: * • active bleeding or hemodynamically unstable at enrollment * signs of chorioamnionitis or clinical infection at enrollment * signs of spontaneous labor or cervical insufficiency at enrollment * spontaneous intrauterine fetal demise * allergy to laminaria or dilapan-s™

Keywords: abortion cervical dilation
single position spine surgery registry

Conditions: Spine Fusion; Spinal Stenosis; Degenerative Disc Disease

Summary: the purpose of this study is to systematically, prospectively compare surgical fusion techniques for thoracolumbar spinal fusion patients and assess long-term patient outcomes and revision rates following surgery.

the goal of this study is to understand how the difference in positioning of a patient intraoperatively, as part of performing an anterior posterior spine fusion surgery, can affect short term and long term outcomes. this will be accomplished through observational techniques that will not affect the care patients will receive for their spinal conditions. patients will be asked to complete health and wellness surveys before and after survey to determine how they are doing before surgery and then what if any changes their respective surgeries have had on their lives. further spine x-rays that they have taken to plan their surgeries and assess their recovery will be measured, when available. x-rays will not be taken only for research purposes. additionally aspects of their surgeries will be noted such as where hardware is placed and how long different parts of the surgery took. follow-up is planned to be out to 10 years post-operatively with the goal of collecting information about any revision spine surgeries that would happen during those 10 years as well.

Eligibility criteria:
inclusion criteria: 1. age greater than or equal to 18 years 2. ability to speak and read comfortably in english 3. affliction by a spinal condition warranting evaluation for operative treatment exclusion criteria: 1. current incarceration 2. individuals incapable of consenting and/or objectively responding to surveys, irrespective of reasonable assistance 3. women currently pregnant or expecting to become pregnant in the near future 4. subjects participating in another research study, whose protocol would conflict with comprehensive participation in this study 5. subjects with psychiatric pathology which may impair judgement or the ability to give informed consent.
a study to evaluate the safety and immunogenicity of inactivated varicella zoster virus (vzv) vaccine in adults with autoimmune disease (v212-009)

Conditions: Herpes Zoster

Summary: this is a study to evaluate the safety and immunogenicity of v212 vaccine in adults with autoimmune disease, including participants with rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis, and other similar diseases. the primary hypothesis is that vaccination with v212 vaccine will elicit significant vzv-specific immune responses at approximately 28 days after vaccination 4. the statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is \>1.0.


Eligibility criteria:
inclusion criteria: * diagnosed with an autoimmune disease * clinically stable disease for at least 30 days before enrollment * not likely to undergo hematopoietic stem cell transplantation during the study period * receiving at least one parenteral or oral biologic agent, such as a tumor necrosis factor (tnf) alpha inhibitor, or a parenteral or oral non-biologic therapy, at a stable dose for at least 3 months, with no planned or anticipated changes * history of varicella, antibodies to vzv, or residence for at least 30 years in a country with endemic vzv infection, or if participant is less than 30 years old, attended primary or secondary school in a country with endemic vzv infection exclusion criteria: * prior history of herpes zoster (shingles) within 1 year before enrollment * prior varicella or zoster vaccine * active central nervous system lupus erythematosus requiring therapeutic intervention within 90 days of enrollment * prior or planned therapy containing rituximab or other anti-cluster of differentiation (cd) 20 monoclonal antibodies from 3 months before enrollment through 28 days postdose 4 * systemic corticosteroid therapy, prednisone, or equivalent over 40 mg daily at the time of enrollment

Keywords: shingles
value of the combination ultrasonography with ti-rads score / dual tracer scintigraphy mibi-tc99m/iodine-123 in the detection of malignancy of thyroid nodules (≥15 mm) classified bethesda iii or iv on cytology

Conditions: Malignancy of Thyroid Nodules

Summary: the main objective of the study is to show that the addition of ultrasonography to the dual tracer scintigraphy mibi-tc99m/iodine-123 will increase (at least +5%) the negative predictive value compared to the dual tracer scintigraphy alone in detection of malignancy in thyroid nodules ≥15 mm classified as bethesda iii-iv on cytology.


Eligibility criteria:
inclusion criteria: * any patient over 18 years with a thyroid nodule ≥15 mm (maximal diameter measured on us) with a bethesda class iii or iv (fna less than 6 months before the surgery). * given signed, written informed consent * affiliation to a social security system. * neither-pregnant nor breast-feeding women. * use of efficient contraception for patient with pregnancy potential (if needed). exclusion criteria: * underage and adults under guardianship. * pregnant, without efficient contraception (if needed) or breast feeding women. * administration of iodinated contrast in the previous 3 weeks. * contraindication to scintigraphy or to iodine123/ mibi 99tc administration * treatment containing iodine (i.e. : amiodarone) * hypo or hyperthyroidism treated or not. * nodules inferior 15 mm. * refusal to sign the consent. * refusal of surgical treatment or contraindication for surgery or anesthesia * morbid obesity (bmi superior 40 kg/m2). * hyperparathyroidism. * history of cervicotomy.
comparison of adjuvanted hepatitis b vaccine to double dose of engerix™-b in pre- /haemodialysis patients aged ≥15 years

Conditions: Hepatitis B

Summary: comparison of adjuvanted hepatitis b vaccine to double dose of engerix™-b in pre- /haemodialysis patients aged ≥15 years.


Eligibility criteria:
inclusion criteria: * a male or female \> = 15 years of age at the time of the first vaccination. * written informed consent obtained from the subject/ from the parents or guardians of the subject. * seronegative for anti-hbs antibodies, anti-hbc antibodies \& hepatitis b surface antigen (hbsag). * if the subject was a female, she was of non-childbearing potential or, if of childbearing potential, she had to be abstinent or use adequate contraceptive precautions for one month prior to enrollment and up to two months after the last vaccination. * pre-haemodialysis patient\* or a patient on haemodialysis. exclusion criteria: * use of any investigational or non-registered drug or vaccine other than the study vaccine during the study period or within 30 days preceding the first dose of study vaccine. * previous vaccination against hepatitis b. * history of hepatitis b infection. * known exposure to hepatitis b virus within 6 weeks. pregnant or lactating female * clinically abnormal alt/ast values (\> 3 times normal values)
developing objective fatigue indicators in colorectal cancer survivors.

Conditions: Colorectal Cancer

Summary: the aims of this four-year study are to 1. explore exercise behavior, exercise barriers, and identify the significant factors for exercise behavior in colorectal cancer survivors. 2. explore the relationships among fatigue, muscle strength, and metabolomics and further examine the possible biomarkers from muscle strength and metabolomics for fatigue. 3. develop a clinical guidelines of home-based fatigue management and exercise program and test its effect on decreasing fatigue for patients with colorectal cancer after surgery in taiwan.


Eligibility criteria:
inclusion criteria: * colorectal cancer survivors completed treatment at least 3 months in clinics. * aged above 20. exclusion criteria: * kps \< 60 * stage 4 * bone meta

Keywords: colorectal cancer、fatigue、muscle strength、metabolomics